Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 6, 03 August 2023
Open
Access | Article
The advantages and disadvantages of different types of vaccines: DNA vaccine, mRNA vaccine, and inactivated vaccine
* Author to whom correspondence should be addressed.
Abstract
The use of vaccines to combat disease by humans has been ongoing for centuries and has produced significant results. However, with the development of technology, different types of vaccines have emerged, and often people are confused as to which is the best. This paper have analyzes three main types of vaccines that have been developed and commercialized: DNA vaccines, mRNA vaccines, and inactivated vaccines, to gain insight into the issues associated with vaccines. This paper explained the mechanisms of action and the process of their production, and identified some of their potential advantages and disadvantages. Finally, this study draw the conclusion that each type of vaccine has unique properties that cannot be replaced by others and that it was not easy to determine the best among them.
Keywords
vaccine, mechanism of action, manufacture, plasmid, immunize
References
1. WHO COVID19 Vaccine Tracker. [(accessed on 9 February 2022)]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
2. Henrique Roman Ramos and Paulo Lee Ho. "Developing Snake Antivenom Sera by Genetic Immunization: A Review". Clinical Toxinology in Asia Pacific and Africa, pp. 401–414 (2015).
3. Shuying Liu, Shixia Wang, Shan Lu. "DNA immunization as a technology platform for monoclonal antibody induction". Emerging Microbes & Infections, 5 (4): e33 (April 27, 2016).
4. Deep, Shukla, “DNA vs. mRNA vaccines: Similarities and differences”, (2021). https://www.medicalnewstoday.com/articles/dna-vs-mrna-vaccines-similarities-and-differen ces
5. “PLASMID”, National Human Genome Research Institute, (2023). https://www.genome.gov/genetics-glossary/Plasmid.
6. Smriti Mallapaty, “India’s DNA COVID vaccine is a world first – more are coming”, nature, (2021). https://www.nature.com/articles/d41586-021-02385-x.
7. Haiqing, Bai, Gillian, M. Schiralli Lester, Laura, C. Petishnok and David A. Dean. “Cytoplasmic transport and nuclear import of plasmid DNA”, Bioscience Reports (2017).
8. Lechardeur, D., Sohn, K.J., Haardt, M., Joshi, P.B., Monck, M., Graham, R.W. et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther. 6, 482–497 (1999).
9. Delphine Lechardeur, Gergely L. Lukacs. “Nucleocytoplasmic transport of plasmid DNA: a perilous journey from the cytoplasm to the nucleus”. National Library of Medicine (2006).
10. Fisman, D.N.; Savage, R.; Gubbay, J.; Achonu, C.; Akwar, H.; Farrell, D.J.; Crowcroft, N.S.; Jackson, P. “Older age and a reduced likelihood of 2009 H1N1 virus infection”. N. Engl. J. Med. (2009).
11. Xu, R.; Ekiert, D.C.; Krause, J.C.; Hai, R.; Crowe, J.E., Jr.; Wilson, I.A. “Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus” (2010).
12. Jose, M. Jimenez-Guardeño, Jose A. Regla-Nava, Jose L. Nieto-Torres, Marta L. DeDiego, Carlos Castaño-Rodriguez, Raul Fernandez-Delgado, Stanley Perlman, Luis Enjuanes. “Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine” (2015).
13. Takeshi Tsubata. “Role of inhibitory B cell co-receptors in B cell self-tolerance to non-protein antigens” (2022).
14. Rubens, López. “Pneumococcus: the sugar-coated bacteria” (2006).
15. David, Verga, “mRNA and the future of vaccine manufacturing”, PATH (2021).
16. Ryan Marshall, Colin S.Maxwell, Scott P.Collins, etc. Rapid and Scalable Characterization of CRISPR Technologies Using an E. coli Cell-Free Transcription-Translation System. Molecular Cell, 2018. 69: 146-157. https://doi.org/10.1016/j.molcel.2017.12.007.
17. David P. Clark, Michelle R. McGehee, et al. “Plasmids (in “Molecular Biology”)”, Third edition (2019).
18. Lisa, Coon. “What is a booster shot and why do I need it?”. OSF healthcare (2022). https://www.osfhealthcare.org/blog/covid-19-booster-shots/.
19. Pollard A.J., Bijker EM. "A guide to vaccinology: from basic principles to new developments". Nature Reviews. Immunology (2021).
20. Karch, C.P., Burkhard, P. "Vaccine technologies: From whole organisms to rationally designed protein assemblies". Biochemical Pharmacology (2016).
21. Government of Canada, “National Vaccine Storage and Handling Guidelines for Immunization Providers” (2015). https://www.canada.ca/en/public-health/services/publications/healthy-living/national-vaccine -storage-handling-guidelines-immunization-providers-2015.html#ack
22. Edward PK. Parker, Natalie A. Molodecky, Margarita Pons-Salort, Kathleen M. O’Reilly, and Nicholas C Grassly. “Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame”. Expert Rev, Vaccines (2015).
23. Cynthia A. Challener. “A Look at Genetic Vaccine Development and Manufacturing”. pharma’s almanac (2021). https://www.pharmasalmanac.com/articles/a-look-at-genetic-vaccine-development-and-man ufacturing.
24. “Plasmid DNA Downstream Process--For gene therapy and plasmid-base DNA vaccine development”. Merck KGaA (2021).
25. Duarte Miguel F. Prazeres , Gabriel A Monteiro. “Plasmid Biopharmaceuticals” (2014).
26. Bertrand Beckert, Benoît Masquida. “Synthesis of RNA by in vitro transcription”, (2011).
27. Thomas Schlake, Andreas Thess, Mariola Fotin-Mleczek, and Karl-Josef Kallen. “Developing mRNA-vaccine technologies”. National Library of medicine (2012).
28. Peng J., Schoenberg D.R. “mRNA with a <20-nt poly(A) tail imparted by the poly(A)-limiting element is translated as efficiently in vivo as long poly(A) mRNA”, National Library of Medicine (2005).
29. Lonza, “Vaccine Manufacturing...Creating Immunity to Fight Off Diseases”. LONZA, Pharma & Biotech. https://bioscience.lonza.com/lonza_bs/HK/en/vaccine-manufacturing.
30. Brown, F., “Review of accidents caused by incomplete inactivation of viruses”. National Library of Medicine, (1993).
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
- ISBN (Print)
- 978-1-915371-65-2
- ISBN (Online)
- 978-1-915371-66-9
- Published Date
- 03 August 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/6/20230193
- Copyright
- 03 August 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited